Evidence map›Paper›PMID 41666132›Full record

ArticlePLOS global public health2026

Access to pediatric medicines in Albania: A qualitative study of family doctors' perceptions.

Eriona Petro, Hendrika A van den Ham, Aukje K Mantel-Teeuwisse, Harallamb Martopullo, Iris R Joosse, Fatima Suleman

Abstract read
In one paragraph

Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eriona PetroLocal Healthcare Unit, Durres, Albania.ORCID https://orcid.org/0009-0003-1471-3861
Hendrika A van den HamWHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0003-1339-9818
Aukje K Mantel-TeeuwisseWHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0002-8782-0698
Harallamb MartopulloPrimary Healthcare Center Nr.4, Durres, Albania.
Iris R JoosseWHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0001-7677-8589
Fatima SulemanWHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.ORCID https://orcid.org/0000-0002-8559-9168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Access to pediatric medications remains a challenge in Albania, with significant implications for child health outcomes. Family doctors often encounter difficulties in prescribing and ensuring access to appropriate treatments. This study aimed to explore prescriber perspectives on the accessibility of pediatric medicines in Albania and to identify key barriers and facilitators affecting access. Between March and April 2024, semi-structured interviews were conducted with 18 family doctors working in primary healthcare centers in Durrës. Data were analyzed deductively using the Pharmaceutical Value Chain framework, enhancing the methodological rigor of the analysis. Participants identified a range of perceived barriers, including regulatory constraints, pricing issues, limited medicine selection, procurement inefficiencies, and reimbursement challenges. Affordability emerged as a major concern, particularly for low-income families, and directly influenced prescribing behaviors. Shortages, especially of antibiotics frequently necessitated alternative treatments. While some pediatric medicines were available, concerns about the range, formulation, and quality persisted. Facilitators of access included effective patient counseling and clear communication between prescribers and pharmacists. Notably, policy, legislation, and health information technology were not identified as barriers by participants. This study highlights multiple perceived obstacles to pediatric medicine access as reported by prescribers. Findings underscore the need to enforce prescription regulations and update reimbursement policies for pediatric medicines, thereby informing future evidence-based policy interventions aimed at improving child health outcomes in Albania.

Identifiers

PMID41666132
PMCPMC12890106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.